New Oral Weight Loss Drugs: Where Are We and What's Next?
Jun 5, 2024 · Now that semaglutide (Wegovy), tirzepatide (Zepbound), and other injectables have created an insatiable market for weight loss drugs, biotech and pharmaceutical companies are roaring ahead with ...
Point-of-Care Medical Reference App For Doctors - Medscape
2 days ago · Check drug interactions, access 450+ medical calculators, and ID pills at the point-of-care with Medscape's official app. No hidden costs or subscription fees.
Pharmacists - Medscape
Pharmacists : Welcome to Medscape Pharmacists, where you can peruse the latest medical news, commentary from clinician experts, major conference coverage, full-text journal articles, and trending ...
Physician Compensation Report 2023 - Medscape
: The Medscape Physician Compensation Report is the physician-preferred salary report, based on the most comprehensive and widely used doctors’ salary survey in the US for the 13th straight year.
Latest Medical News, Clinical Trials, Guidelines - Medscape
Today on Medscape : Get the latest medical news, clinical trial coverage, drug updates, journal articles, CME activities & more on Medscape. A free resource for physicians.
Ketamine vs Esketamine: Critical Differences Explained - Medscape
Jan 19, 2024 · In recent years, media reports touting ketamine as a fast-acting, highly effective treatment for severe depression have increased. In part, this phenomenon is due to the US Food and Drug ...
Medscape – Help | CME
Dec 18, 2024 · How Do I Participate in CME/CE Activities? Select an online activity available for CME, nursing CE, or pharmacy CE credit. Read the goal and/or learning objectives.
Medscape Home Pages
Medscape Today - Daily news and feature updates, with the latest CME activities, and more.
Medscape – Help | Accounts
4 days ago · Update Profile Info. It is possible for Medscape members to change their own account information. Using the Edit Your Profile option, you can change your MedPulse subscription status, change your ...
Denosumab Raises Hypocalcemia Risk in Chronic Kidney Disease
Nov 21, 2024 · The risk for emergently treated hypocalcemia in individuals receiving denosumab peaked at 2 weeks after administration and returned to its baseline level by around 10 weeks.